Literature DB >> 15920131

No cure, no pay.

Claus Møldrup1.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 15920131      PMCID： PMC558101          DOI： 10.1136/bmj.330.7502.1262

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

Review 1.  Ethical, social and legal implications of pharmacogenomics: a critical review.

Authors:  Claus Moldrup
Journal:  Community Genet       Date:  2001

2.  "Me-too" products--friend or foe?

Authors:  Thomas H Lee
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

3.  Healthcare reform through rationing.

Authors:  Elizabeth J Floyd
Journal:  J Healthc Manag       Date:  2003 Jul-Aug

4.  The health cost of doing business.

Authors:  J A Califano
Journal:  Health Matrix       Date:  1985

5.  Academic medicine must deal with the clash of business and professional values.

Authors:  H M Swick
Journal:  Acad Med       Date:  1998-07       Impact factor: 6.893

6.  Success rates for new drugs entering clinical testing in the United States.

Authors:  J A DiMasi
Journal:  Clin Pharmacol Ther       Date:  1995-07       Impact factor: 6.875

7.  Merck offers money back guarantee on finasteride.

Authors:  A Tonks
Journal:  BMJ       Date:  1994-11-12

Review 8.  Medicine as a business.

Authors:  Merrill Matthews
Journal:  Mt Sinai J Med       Date:  2004-09
  8 in total
  6 in total

1.  Rationing of drugs for rare diseases.

Authors:  Dyfrig Hughes
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.

Authors:  Adrian Towse; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Authors:  Tania Stafinski; Christopher J McCabe; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 4.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655

5.  Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan.

Authors:  Alexander T Sandhu; Paul A Heidenreich; John Lin; Justin Parizo; Jay Bhattacharya; Jeremy D Goldhaber-Fiebert
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2022-01-18

6.  What do patients want from their psychiatrist? A cross- sectional questionnaire based exploratory study from Karachi.

Authors:  Roomasa Channa; Mn Siddiqi
Journal:  BMC Psychiatry       Date:  2008-02-29       Impact factor: 3.630
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.